Sepsis, coagulation, and antithrombin: Old lessons and new insights

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 8, 2008, Pages 742-746

  Levi, Marcel ^a   Schouten, Marcel ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antithrombin; Coagulation; Sepsis; Thrombosis

Indexed keywords

ANTITHROMBIN; DROTRECOGIN; HEPARIN; PLACEBO;

ANTICOAGULATION; BLOOD CLOTTING; CLINICAL TRIAL; DOWN REGULATION; DRUG MEGADOSE; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; SEPSIS;

EID: 60549086978     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1145256     Document Type: Review

References (54)

1. Strieter RM, Lynch JP III, Basha MA, Standiford TJ, Kasahara K, Kunkel SL. Host responses in mediating sepsis and adult respiratory distress syndrome. Semin Respir Infect 1990;5:233-247
2. Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother 1998;41(Suppl A):17-24
3. Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci 2000;13:239-245
4. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-214
5. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-2704
6. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195
7. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26-39
8. Robboy SJ, Major MC, Colman RW, Minna JD. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol 1972;3:327-343
9. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983;107:543-547
10. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2856
11. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997;89:4393-4401
12. Taylor FBJ, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-134
13. Taylor FBJ, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
14. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;164:1988-1996
15. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002;26:650-658
16. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592
17. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
18. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008;34:459-468
19. Laterre PF, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost 2006; 32:71-76
20. Taylor FBJ, Dahlback B, Chang AC, et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995;86:2642-2652
21. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32(Suppl 1):49-60
22. Levi M, Dorffler-Melly J, Reitsma PH, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 2003;101:4823-4827
23. Mammen EF. Antithrombin III and sepsis. Intensive Care Med 1998;24:649-650
24. Balk R, Emerson T, Fourrier F, et al. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost 1998;24:183-194
25. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25
26. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998;24:61-69
27. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000;95:1117-1123
28. Taylor FBJ, Emerson TEJ, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
29. Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin Pharmacol Ther 2006;79:23-34
30. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
31. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-164
32. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003;101:3029-3036
33. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96:2302-2310
34. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-259
35. Nieuwdorp M, Meuwese MC, Mooij HL, et al. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2008;202:296-303
36. Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 2000;101:1500-1502
37. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003;92:592-594
38. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-56
39. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29:S90-S94
40. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-886
41. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
42. Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art. Thromb Haemost 1999;82:695-705
43. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878
44. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985;39:81-89
45. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-1037
46. Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 2006;57:260-265
47. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006;6:633-643
48. Gotte M. Syndecans in inflammation. FASEB J 2003;17:575-591
49. Lindahl U. Heparan sulfate-protein interactions - a concept for drug design? Thromb Haemost 2007;98:109-115
50. Xie X, Rivier AS, Zakrzewicz A, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 2000;275:34818-34825
51. Levi M. Antithrombin in sepsis revisited. Crit Care 2005;9:624-625
52. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-2059
53. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330
54. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-1933